Navigation Links
American Oriental Bioengineering Announces Participation in September Investor Conferences
Date:9/4/2007

NEW YORK, Sept. 4 /PRNewswire-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: AOB), a leading manufacturer and distributor of plant-based pharmaceutical and nutraceutical products in China, today announced that the Company will attend the Credit Suisse Asian Technology Conference -- China Day on September 10, 2007 in Shenzhen, China as well as the 3rd Semi-Annual Investor Tour of Mainland China hosted by Brean Murray Carret & Co. on September 11, 2007 in Beijing, China.

AOBO management will meet individually with institutional investors attending the Credit Suisse Asian Technology Conference at the Crowne Plaza Hotel in Shenzhen, China on September 10, 2007. In addition, Tony Liu, CEO of AOBO will join a lunch panel discussion at 1:00 pm Beijing Standard Time along with presenters from other Chinese healthcare companies to discuss the recent developments in the China's healthcare industry. Investors interested in attending this event should contact their Credit Suisse institutional sales representative.

AOBO management is scheduled to present at the Brean Murray China Tour on September 11, 2007 at 12:00 pm Beijing Standard Time at the Grand Hyatt Hotel in Beijing. Attendees are also invited to tour the Company's pharmaceutical manufacturing facility and nutraceutical manufacturing facility in Harbin, China on Saturday, September 8, 2007. Investors interested in attending this event should contact their Brean Murray institutional sales representative.

ABOUT AMERICAN ORIENTAL BIOENGINEERING INC:

American Oriental Bioengineering Inc. (AOBO) is engaged in the development and production of plant-based pharmaceutical products and plant-based nutraceutical products widely distributed throughout China. For more information, visit http://www.bioaobo.com.

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.


'/>"/>
SOURCE American Oriental Bioengineering, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. A disgusting video: U.S. companies sell out Americans
2. Northwestern Mutual, American Family make Computerworlds best IT workplaces
3. Brazilian bio-industry should impress American investors
4. CIO Leadership Series: Byrne Chapman, American Family Insurance
5. Metavante fires 180 North American workers
6. 300 millionth American no cause for eco-alarm
7. American Idol spurs music software
8. Healthcare software addresses "90 million" misclassified Americans
9. Technology and the "American" dream
10. Peters: Innovation the only edge that remains for American business
11. We are American No sex, please
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... Linda, Ca (PRWEB) , ... March 21, 2017 ... ... and clearance of biologics. To acquire information on the desired increase and/or decrease ... the biopharmaceutical industry for rapid N-glycosylation profiling of therapeutic antibodies. , To ...
(Date:3/22/2017)... ... 21, 2017 , ... Functional near-infrared spectroscopy (fNIRS), an optical imaging tool for ... to track the brain’s response to acute pain in adults and infants. , In ... published today in the journal Neurophotonics , by SPIE, the international society ...
(Date:3/22/2017)... Mass. , March 22, 2017  RXi ... developing innovative therapeutics that address significant unmet medical ... RXi,s Chief Business Officer, will present at the ... forum will provide a platform to present to ... institutes, leading pharmaceutical and biotech companies as well ...
(Date:3/20/2017)... ... March 20, 2017 , ... Avexegen ... today announced that it has entered into an exclusive global license agreement with ... disease including Necrotizing Enterocolitis (rare orphan disease) as well as Crohn’s Disease and ...
Breaking Biology Technology:
(Date:3/7/2017)... 2017   HireVue , the leading provider of ... the best talent, faster, today announced the additions of ... and Diana Kucer as Chief Marketing Officer ... team poised to drive continued growth in the company,s ... of record bookings in 2017. "Companies worldwide ...
(Date:3/2/2017)... , March 2, 2017 Summary ... understand Perrigo and its partnering interests and activities since 2010. ... Read ... Deals and Alliance since 2010 report provides an in-depth insight ... life sciences companies. On demand company reports are ...
(Date:3/2/2017)... 2017 Who risk to be deprived of ... full report: https://www.reportbuyer.com/product/4313699/ WILL APPLE AND ... Fingerprint sensors using capacitive technology represent a fast ... Idex forecasts an increase of 360% of the number ... the fingerprint sensor market between 2014 and 2017 (source ...
Breaking Biology News(10 mins):